📬 GYN Oncology Intelligence Digest — Week 2026-W31

KEYNOTE-C93 pembrolizumab monotherapy data in dMMR endometrial cancer drew continued debate over the chemotherapy control arm, a FIGO 2023 staging analysis reported 26.0% of endometrial cancers upstaged, RUBY four-year follow-up was presented at SGO 2026, and Study420 reported carboplatin-mirvetuximab outcomes in FRα+ platinum-sensitive ovarian cancer.

⚡ TL;DR

🐦 Twitter / 🦋 Bluesky

Update: KEYNOTE-C93 discussion shifts to whether a chemotherapy-alone control arm is still a fair comparator in dMMR endometrial cancer — Phase 3 KEYNOTE-C93 showed pembrolizumab monotherapy significantly improved PFS versus platinum-based chemotherapy in previously untreated advanced or recurrent dMMR endometrial cancer
Study420 at ESMO Gynae 2026: carboplatin plus mirvetuximab in FRα+ platinum-sensitive ovarian cancer, with prior PARPi exposure parsed — Study420 evaluated carboplatin-mirvetuximab in FRα+ platinum-sensitive ovarian cancer with N=120 and roughly 50% prior PARPi exposure
Update: New analysis quantifies FIGO 2023 endometrial cancer restaging — 26.0% upstaged and superiority over FIGO 2009 not established — Under FIGO 2023, 26.0% of endometrial cancers were upstaged and 4.8% were downstaged
RUBY four-year follow-up at SGO 2026 shows durable benefit of dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer — Four-year follow-up from the RUBY trial showed patients with dMMR/MSI-H primary advanced or recurrent disease continued to demonstrate durable benefit with dostarlimab plus carboplatin/paclitaxel

Full details below ↓

📄 What's Being Published

Manuscripts:

Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity. — Sridhar Sriram et al., Clin Cancer Res

Although TF expression is required for tisotumab vedotin binding to tumor cells, clinical responses were found to be independent of TF levels in recurrent/metastatic cervical cancer. Higher expression of gene signatures linked to natural killer cells and myeloid cells was associated with improved clinical outcomes. In vitro, tisotumab vedotin induced tumor cell death through myeloid-mediated antibody-dependent cellular phagocytosis and natural killer-mediated antibody-dependent cellular cytotoxicity across various TF expression levels.

Clinical bottom line: This biomarker analysis of innovaTV 204 pins tisotumab vedotin activity to immune effector mechanisms rather than tissue factor level, so TF expression should not be used to select cervical cancer patients for the ADC.

Read full article →

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies. — Sweis Randy F et al., J Immunother Cancer

68 patients were enrolled in 10 dose-escalation cohorts (n=56; 64% ovarian carcinoma) and one ovarian expansion cohort (n=12). While MAGE-A4 expression was observed in most patients' tumors (71% positive), the level of expression was low (median H-score=16). At doses ≥90 µg, patients with MAGE-A4+ ovarian cancer had deeper reductions in tumor size and circulating tumor DNA and trended toward longer overall survival than patients with MAGE-A4− ovarian cancer, and there were no treatment-related discontinuations or deaths.

Clinical bottom line: IMC-C103C was tolerable and produced MAGE-A4-dependent activity in ovarian carcinoma, but the low target expression in the higher dosing cohorts blunted any firm efficacy read.

Read full article →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

Update: KEYNOTE-C93 discussion shifts to whether a chemotherapy-alone control arm is still a fair comparator in dMMR endometrial cancer

The Phase 3 KEYNOTE-C93 trial showed pembrolizumab monotherapy significantly improved progression-free survival compared with platinum-based chemotherapy in patients with previously untreated advanced or recurrent dMMR endometrial cancer; the interim analysis also showed a positive trend in overall survival with no new safety signals. As is increasingly the case in oncology, the control arm reflects a previous standard of care, and clinicians note that the more relevant comparator today would likely be chemoimmunotherapy rather than chemotherapy alone. The debate extends to a practical conundrum for active clinical trials requiring platinum as standard, and whether chemotherapy can simply be added back later — questions that remain unresolved given that chemotherapy-free immunotherapy and chemoimmunotherapy have never been compared head to head in this population.

Discussed by: @EladSharonMD, @MAvilaMD, @OncoAlert, @CancerNetwrk

→ View representative tweet

Study420 at ESMO Gynae 2026: carboplatin plus mirvetuximab in FRα+ platinum-sensitive ovarian cancer, with prior PARPi exposure parsed

Study420 evaluated carboplatin plus mirvetuximab in FRα+ platinum-sensitive ovarian cancer with N=120 and approximately 50% prior PARPi exposure; prior PARPi alone did not impact outcomes, but patients progressing during PARPi had lower ORR and PFS. The data prompted discussion about whether progression on a PARP inhibitor — rather than prior PARPi exposure per se — should be the operative discriminator when selecting patients for this combination. More broadly, ADCs are increasingly standard treatments in ovarian and cervical cancers, with clinicians identifying carefully selecting trials for phase III, developing predictive biomarkers, optimizing ADC constructs and targets, and addressing biomarker heterogeneity as priorities.

Discussed by: @AinhoaMada, @OncoAlert, @JaniceTNBCmets

→ View representative tweet

Update: New analysis quantifies FIGO 2023 endometrial cancer restaging — 26.0% upstaged and superiority over FIGO 2009 not established

Under FIGO 2023, 26.0% of endometrial cancers were upstaged and 4.8% were downstaged; with 21 substages, the system is described as overly complex, producing small subgroups and unstable estimates. Superiority over FIGO 2009 could not be established, leaving oncologists to weigh whether adjuvant decisions should still be driven by FIGO 2023 substage when a quarter of patients carry a different stage designation under the new system. A society review addresses how to best incorporate elements of both the 2009 and 2023 FIGO staging strategies in response to these tensions.

Discussed by: @IJGConline, @gynoncjnls

→ View representative tweet

RUBY four-year follow-up at SGO 2026 shows durable benefit of dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer

New data presented at the SGO 2026 Annual Meeting on Women's Cancer describe the sustained impact of adding dostarlimab to chemotherapy for patients with primary advanced or recurrent endometrial cancer. At four-year follow-up from the RUBY trial, patients with dMMR/MSI-H primary advanced or recurrent disease continued to demonstrate durable benefit with dostarlimab plus carboplatin/paclitaxel, reinforcing this regimen as a treatment option. The durability data now sit alongside KEYNOTE-C93's chemotherapy-free pembrolizumab result in dMMR endometrial cancer, without a direct head-to-head comparison to resolve which approach is preferable for the same patients.

Discussed by: @womenofteal, @OncologyTimes

→ View representative tweet

🔥 Top Ranked Tweets

OncoAlert @OncoAlert

RT @OncoAlert: NEWS FROM INDUSTRY: KEYNOTE-C93 Update in #EndometrialCancer
Source: Merck press release

The Phase 3 KEYNOTE-C93 trial showed pembrolizumab monotherapy significantly improved progression-free survival compared with platinum-based chemotherapy in patients with previously untreated advanced or recurrent endometrial cancer with mismatch repair deficient (dMMR) tumors. The study demonstrated meaningful response rates, complete responses, and durable responses, with a safety profile consistent with prior pembrolizumab studies. Results suggest a potential chemotherapy-free frontline treatment option for this patient population.

https://t.co/1eUPTPKiNh

@agz_eriksson
@ESGO_society
@IJGConline
@NicoloBizzarri
@nataliagandur
@realbowtiedoc
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@amandaNizamMD
@DrVilmaPBarcia

🔖 4 ❤️ 17 🔁 9 👁 2,903